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Abstract
Background: According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to
achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is
a combination of sofosbuvir and NS5A inhibitors. Polish national recommendations also allow the use of
paritaprevir/ritonavir/ombitasvir+dasasbuvir±ribavirin (PrODR) in this group of patients. The aim of the study was to
evaluate the efficacy and safety of PrODR vs. ledipasvir/sofosbuvir±RBV (LSR) in PI-experienced patients in real-life
setting.
Methods: Our analysis included patients registered in the nationwide, investigators initiated, multicentre EpiTer-2
database.
Among 4530 patients registered, 335 with genotype 1 (93% 1b) were previously treated with IFN-based regimens
with PIs: 127 with boceprevir (BOC), 208 with telaprevir (TVR).
Patients with advanced fibrosis (F3/F4) were significantly predominant (BOC 28.4%/61.4%, TVR 18.8%/64.4%,
respectively).
Subjects were assigned to IFN-free retreatment as follows: BOC - 64 (50.4%) PrODR and 63 (49.6%) LSR; TVR- 103
(49.5%) PrODR and 105 (50.5%) LSR.
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Results: SVR rates were comparable for particular groups: BOC→ PrODR- 100%; BOC→ LSR - 98%; TVR→ PrODR -
97%; TVR→ LSR - 96% (intent-to treat analysis-ITT) and BOC→ PrODR→100%; BOC→ LSR - 99%; TVR→ PrODR -
99%; TVR→ LSR - 98% (modified intent-to treat analysis-mITT).
Both treatment regimens had a favourable safety profile. Adverse events (AEs) were generally mild or moderate in
severity. Three deaths were reported. The treatment was stopped due to AEs in five patients (three treated with
PrODR and two with LSR).
Conclusion: Efficacy and safety of treatment with PrODR and LSR is comparable in BOC or TVR-experienced
patients.
Keywords: Chronic hepatitis C, Liver cirrhosis, Protease inhibitors, Retreatment, Sustained virologic response
Background
Progress achieved in recent years in the treatment of pa-
tients with viral hepatitis C has enabled elimination of
hepatitis C virus (HCV) infection in most patients. This
progress has been achieved through the use of drugs that
produce a direct antiviral action (direct-acting antivirals-
DAAs). These therapies are highly effective even in pa-
tients with advanced fibrosis, as well as hepatic insuffi-
ciency. Effective therapy inhibits progression of the
disease, often leading to a fibrosis regression [1–4].
The efficacy of DAA-based therapies can be reduced by
the presence of substitutions causing drug resistance (re-
sistance-associated substitutions-RASs) [5–7]. Such substi-
tutions can occur in patients untreated previously;
however, their occurrence is more often associated with in-
effective antiviral therapy, which involved DAAs with a low
genetic barrier, for example first-generation protease inhib-
itors (PI) such as boceprevir (BOC) or telaprevir (TVR).
These drugs were the first DAAs used with pegylated
interferon (PegIFN) and ribavirin (RBV) in antiviral ther-
apies for patients infected with HCV genotype 1.
In the following years, drugs belonging to other classes
and having other mechanism of action disrupting the
process of HCV replication were introduced: polymerase
inhibitors and non-structural protein 5A (NS5A) inhibi-
tors. The combined use of drugs belonging to 2 or 3
therapeutic groups allowed the development of effective
and safe interferon-free regimens.
In patients who had already undergone ineffective
BOC or TVR triple therapy, there was a risk of reduced
efficacy of subsequent IFN-free therapies in which one
of the components was a protease inhibitor due to the
RASs generated during the first use of these drugs.
According to the guidelines of the European Associ-
ation for the Study of the Liver (EASL), and the Ameri-
can Association for the Study of the Liver Diseases
(AASLD), the re-use of first-generation protease inhibi-
tors is not recommended in patients who do not re-
spond to these drugs in the past [8, 9].
Recommended therapeutic regimens were combinations
of polymerase and NS5A inhibitors: ledipasvir/sofosbuvir
or daclatasvir+sofosbuvir [8, 9]. These recommendations
were based on the randomized clinical trials findings [10–
13]. Moreover, in this patient group, the EASL recom-
mendations provide for ribavirin addition to the DAAs to
improve efficacy and reduce potential resistance [8].
In Poland, the first and for some time the only therapy
composed of DAAs was paritaprevir/ ritonavir/ombitas-
vir ± dasabuvir ± ribavirin (PrODR), not mentioned in
the above guidelines as recommended for patients after
PI treatment failure.
Initially, this drug combination was used in the early
access program, in patients with advanced fibrosis, the
majority of whom underwent ineffective prior IFN-based
treatment (AMBER study) [14]. Among the patients in-
cluded in this cohort were those who failed triple ther-
apies involving boceprevir or telaprevir. However, the
number of these patients was small. High efficacy ob-
served in this group were considered in the recommen-
dations of the Polish Group of HCV Experts [15] and
caused inclusion of PrODR along with ledipasvir/sofos-
buvir ±RBV (LSR) and sofosbuvir + daclatasvir (SOF +
DCV), to be used in patients with a history of prior
BOC + PegIFN+RBV or TVR + PegIFN+RBV regimens.
In 2015, PrODR and LSR became available (reim-
bursed) for Polish patients, whereas SOF + DCV combin-
ation was not accepted for reimbursement in Poland.
The purpose of this study was to evaluate in the real-
life setting the efficacy and safety of PrODR versus LSR
in patients who failed prior triple IFN-based therapies
with first generation protease inhibitors.
Material and methods
Study population
On the investigators’ initiative, a national EpiTer-2 data-
base of patients receiving antiviral treatment due to
HCV infection in Poland was established in 2016 based
on regimens available within the therapeutic program of
the National Health Fund. Twenty-two hepatology cen-
tres applied for participation in the project. Treatment
efficacy and safety data were collected in the EpiTer-2
web database.
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Demographic data of the patients, information related
to HCV genotype, stage of fibrosis, liver function param-
eters (Child-Turcotte-Pugh and MELD scores), prior
antiviral therapy, concomitant diseases and drugs used
in relation thereto, HBV and/or HIV coinfections were
collected in the database.
Hepatic fibrosis was evaluated by liver biopsy based on
the METAVIR or Scheuer scoring system, transient elas-
tography (TE) using the FibroScan (Echosens, Paris) de-
vice or the real-time shear wave elastography (SWE)
using the Aixplorer (Supersonic, Aix-en-Provence) de-
vice. Among BOC-experienced patients: liver biopsy was
performed in 31 (24.4%), TE in 73 (57.5%), and SWE in
23 (18.1%) patients, and in the TVR group: biopsy was
performed in 44 (21.2%), TE in 138 (66.3%), and SWE in
26 (12.5%) patients.
HCV RNA was monitored prior to and after the treat-
ment (end of treatment virologic response: EOT-VR),
and then after at least 12-week follow-up period (sus-
tained virologic response -SVR). Two assays were used
to measure HCV RNA, depending on local practices at
the testing site: Roche COBAS TaqMan with a lower
limit of quantification (LLOQ) of 15 IU/mL or Abbott
RealTime with an LLOQ of 12 IU/mL.
Adverse events (AEs) observed during the treatment
and follow-up period were reported as well. Criteria for
assessing AEs as serious were: resulting in death, life-
threatening, requiring hospitalisation or prolongation of
existing hospitalization, resulting in persistent or signifi-
cant disability, or congenital anomaly or birth defect.
In 2016 and 2017 up to now, a total of 4530 patients
were registered in the EpiTer-2 database, including 335
patients having failed prior triple-drug regimens with
boceprevir or telaprevir, retreated with interferon-free
regimens PrOD and LSR, being the subject of this study.
Baseline characteristics of the patients are presented in
Table 1. Sex, age, and BMI distribution were similar for
both BOC- and TVR-experienced groups of patients.
Notably, patients with GT1b prevailed significantly in
both groups, which is typical for Polish population [16].
Patients with cirrhosis (F4) and advanced fibrosis (F3)
were predominant, while only few patients showed se-
vere liver impairment symptoms (Child-Turcotte-Pugh
B or C) at the beginning of the therapy or decompensa-
tion in the previous history. The percentage of patients
with confirmed oesophageal varices was similar in both
subgroups.
The choice of the drug, dosage and length of treat-
ment regimen (12 vs. 24 weeks, addition of ribavirin)
was made by the treating physicians based on the applic-
able product characteristics and recommendations of
Polish Group of HCV Experts [15, 17]. All patients
qualified for class B or C of Child-Turcotte-Pugh scoring
system received LSR.
Statistical analysis
Data are presented as absolute numbers (%) or mean ±
standard deviation. No sample size was planned. All pa-
tients who started the treatment were included in the
analysis, and efficacy analyses were performed on an
intent-to-treat (ITT) basis (missing virological measure-
ments were imputed as treatment failures) and modified
intent-to-treat (mITT) basis, which excludes patients
with missing data of sustained virologic response (at
least 12 weeks after treatment completion). The propor-
tion of patients who achieved SVR was calculated. The
significance of difference was calculated by use of Chi-
square or Fischer’s exact test where appropriate. P values
of < 0.05 were considered to be statistically significant.
Statistical analyses were performed with STATIS-
TICA12.0 (Statsoft, Tulsa, OK, USA).
Results
This study focuses on the analysis of the data from the
EpiTer-2 database concerning 335 patients having failed
prior triple, IFN-based regimens with boceprevir or tela-
previr. Patients previously treated with telaprevir con-
taining regimen prevailed (62%) in the cohort (Table 1).
Patients with relapse of infection following prior anti-
viral treatment prevailed in BOC subgroup, while those
with non-response prevailed in TVR subgroup. There
were no patients with HIV coinfection or active HBV
coinfection. Only a few patients had a history of hepato-
cellular carcinoma (one in BOC and four in the TVR
subgroup). Moreover, in both subgroups, there were pa-
tients who began treatment after liver transplantation
(one in BOC and five in the TVR subgroup).
A majority of patients from both subgroups had con-
comitant diseases, most often hypertension and diabetes.
BOC patients (63.8%) and 67.8% of TVR patients were
taking additional drugs due to these diseases.
Different dosage regimens of PrODR or LSR were ap-
plied in this therapy depending on the current guide-
lines. Among 127 BOC patients 64 (50.4%) were being
treated using one of the PrODR (BOC➔PrODR), while
63 (49.6%) patients with LSR regimens (BOC➔LSR). In
the TVR subgroup, 103 (49.5%) patients received PrODR
(TVR➔PrODR) and 105 (50.5%) patients received LSR
(TVR➔LSR). Distribution of these regimens among
studied population is summarized in Table 2.
Treatment efficacy
Figure 1 presents the treatment course and the reasons
of discontinuation.
In both groups, a majority of patients completed the
full course of treatment scheduled and only five patients
(1.5%) had to interrupt it due to adverse events (AEs).
All patients, whose treatment was discontinued, reached
SVR despite the reduced duration of treatment. Only
Janczewska et al. BMC Infectious Diseases          (2018) 18:580 Page 3 of 9
one BOC and two TVR patients (non-responders) failed
to achieve SVR among the total number of 14 patients
in whom HCV RNA was detectable at the end of the
treatment (EOT).
The remaining subjects achieved SVR despite a posi-
tive result at the EOT. This phenomenon, specific for
DAA regimens, was not observed during interferon-
based therapies.
On the other hand, despite of undetectable HCV RNA
at the EOT, 3 patients relapsed. Two patients from BOC
and three from TVR group were lost to follow-up and
evaluation of SVR was not possible.
As shown in Fig. 2, end of treatment virologic re-
sponse (EOT-VR) and SVR evaluated in the ITT analysis
was insignificantly lower in TVR groups.
In the mITT evaluation in BOC group, SVR was 99%
for BOC➔LSR and 100% for BOC➔PrODR, while in
TVR group it was 98% for TVR➔LSR and 99% for
TVR➔PrODR.
Therefore, we can assume that both drugs are highly
effective irrespective of the first-generation protease in-
hibitor which was used in the primary treatment.
Treatment safety
The most important adverse events (AEs) that occurred
during the treatment and in the follow-up period are
summarized in Table 3.
These were observed in 52 patients of BOC group and
in 99 patients of TVR group. Severity was generally mild
or moderate. Fatigue, headache, and anaemia prevailed,
Table 1 Baseline Characteristics of 335 Patients Included in the
Study
Parameter Boceprevir-
experienced
Telaprevir-
experienced
Number of patients, n (%) 127 (38%) 208 (62%)
Gender: females/males, n (%) 63 (49.6%)/65
(50.4%)
95 (45.7%)/ 113
(54.3%)
Age (years) mean ± SD; min-max 55.4 ± 10.9; 23–74 60.3 ± 10.7; 27–78
BMI mean ± SD; min-max 27.4 ± 4.99; 19–38 27.6 ± 4.11; 19–44
HCV Genotype: n (%)
1b 120 (94.5%) 191 (91.8%)
1a 5 (3.9%) 9 (4.3%)
1 2 (1.6%) 8 (3.9%)
Fibrosis, n (%)
F4 78 (61.4%) 134 (64.4%)
F3 36 (28.4%) 39 (18.8%)
F2 9 (7.1%) 19 (9.1%)
F1 4 (3.1%) 16 (7.7%)
Child-Turcotte-Pugh, n (%)
A 123 (96.9%) 201 (96.6%)
B 4 (3.1%) 5 (2.4%)
C 0 (0%) 2 (1%)
Response to previous treatment with PI+PegIFN+RBV, n (%)
Non-response 45 (35.4%) 83 (39.9%)
Relapse 48 (37.8%) 66 (31.7%)
Discontinuation 17 (13.4%) 37 (17.8%)
Unknown 17 (13.4%) 22 (10.6%)
History of hepatic
decompensation, n (%)
9 (7.1%) 11 (5.3%)
Ascites 9 (7.1%) 9 (4.3%)
Encephalopathy 0 (0%) 2 (1%)
Documented oesophageal
varices, n (%)
21 (16.5%) 47 (22.6%)
History of hepatocellular
carcinoma, n (%)
1 (0.8%) 4 (1.9%)
HBV coinfection, n (%)
HBsAg positive 4 (3.1%) 0 (0%)
HBV DNA positive 0 (0%) 0 (0%)
Anti-HBc positive 11 (8.7%) 17 (8.2%)
HIV coinfection, n (%) 0 (0%) 0 (0%)
History of liver transplantation, n
(%)
1 (0.8%) 5 (2.4%)
Comorbidities, n (%)
Any comorbidity 87 (68.5%) 142 (68.3%)
Hypertension 48 (37.8%) 82 (39.4%)
Diabetes 17 (13.4%) 34 (16.3%)
Renal insufficiency 1 (0.8%) 2 (1%)
Autoimmune diseases 2 (1.6%) 2 (1%)
Table 1 Baseline Characteristics of 335 Patients Included in the
Study (Continued)
Parameter Boceprevir-
experienced
Telaprevir-
experienced
Non-HCC tumours 1 (0.8%) 0 (0%)
Other 21 (16.5%) 46 (22.1%)
Concomitant medications, n (%) 81 (63.8%) 141 (67.8%)
Table 2 Current Treatment Regimens
Treatment regimen Boceprevir-
experienced
Telaprevir-
experienced
LDV/SOF, n (%) n = 63 n = 105
LDV/SOF 12 weeks 11 (8.7%) 26 (12.5%)
LDV/SOF 24 weeks 6 (4.7%) 9 (4.3%)
LDV/SOF + RBV 12 weeks 41 (32.3%) 63 (30.3%)
LDV/SOF + RBV 24 weeks 5 (3.9%) 7 (3.4%)
PrOD, n (%) n = 64 n = 103
PrOD 12 weeks 29 (22.8%) 42 (20.2%)
PrOD+RBV 12 weeks 33 (26%) 56 (26.9%)
PrOD+RBV 24 weeks 2 (1.6%) 5 (2.4%)
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which mainly occurred in the patients treated with thera-
peutic regimens containing ribavirin. Treatment discon-
tinuation due to AE occurred in three patients of the BOC
group and two patients of the TVR group (Fig. 1).
According to the treating physicians’ evaluation, AEs
leading to discontinuation of the treatment in BOC
group, were not associated with the DAA applied, while
persistent vomiting in one TVR patient was probably as-
sociated with PrODR.
The second case (decompensation) was probably asso-
ciated with the baseline stage of the disease rather than
antiviral treatment. It occurred in a patient with a his-
tory of hepatic insufficiency treated with LSR.
Serious adverse events (SAEs) occurred in two patients
from BOC group. One of them, being treated with PrODR,
underwent cholecystectomy due to acute cholecystitis,
which entailed discontinuation of the treatment on the 9th
week. Another patient was diagnosed with cholangiocarci-
noma after completing treatment with LSR and died on the
20th week of the follow-up period.
In TVR group, two patients treated with LSR died of can-
cer during the follow-up period (hepatocellular carcinoma
and pancreatic cancer). Both patients had undetectable HCV
RNA 12 weeks after the treatment end. Portal vein throm-
bosis was detected in one patient treated with PrOD in the
course of the treatment. This patient also achieved SVR.
All SAEs were assessed as irrelevant to the antiviral
treatment and at least SVR12 was confirmed in all of
these patients.
Discussion
The introduction of interferon-free therapy regimens
had a beneficial effect in patients with chronic hepatitis
Fig. 1 Patients’ disposition and reasons for discontinuation. EOT-VR end of treatment virologic response, SVR sustained virologic response, LTFU
lost to follow-up, TF treatment failure, DEC hepatic decompensation, CAD exacerbation of pre-existing coronary arterial disease, AC acute
cholecystitis, VOM-vomiting
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C. These regimens have become highly effective and
safe, irrespective of the severity of liver disease.
In the interferon era, prior treatment failure was an
important factor restricting efficacy of subsequent anti-
viral therapies [18–20]. Introduction of triple-drug regi-
mens significantly increased chances for recovery only in
patients with mild to moderate fibrosis, treatment naïve
or relapsers after PegIFN+RBV therapy. Patients with
cirrhosis and/or lack of virologic response to prior ther-
apy showed significantly worse response to the
interferon-based treatment, which included first gener-
ation PIs [21–25].
Breakthrough was only made through the use of
interferon-free therapies. As specified in the introduc-
tion, international hepatology societies recommend the
use of LSR or SOF + DVC after failed triple-drug
Table 3 Adverse Events
Parameter Boceprevir-experienced Telaprevir-experienced
LDV/SOF
(n = 63)
PrOD
(n = 64)
LDV/SOF
(n = 105)
PrOD
(n = 103)
Patients with at least one AE, n (%) 24 (38.1%) 28 (43,8%) 44 (41.9%) 45 (43.7%)
RBV-containing regimen 18 (28.6%) 19 (29.7%) 31 (29.5%) 33 (32%)
Most common AEs (> 5%), n (%)
Fatigue 15 (23.8%) 17 (26.6%) 27 (25.7%) 30 (29.1%)
Anaemia 9 (14.3%) 13 (20.3%) 15 (14.3%) 22 (21.4%)
Headache 8 (12.7%) 11 (17.2%) 10 (9.5%) 12 (11.7%)
Nausea 4 (6.3%) 4 (6.3%) 7 (6.7%) 8 (7.8%)
Serious AEs, n (%) 1 (1.6%) 1 (1.6%) 2 (1.9%) 1 (1%)
Deaths 1 (1.6%) 0 (0%) 2 (1.9%) 0 (0%)
Fig. 2 Treatment outcome. End of treatment virologic response (EOT-VR) and sustained virologic response (SVR) rate; ITT—intent-to-treat analysis,
which included all patients receiving at least 1 dose of the treatment, mITT—modified ITT analysis, which excluded patients with missing data of
sustained virologic response (at least 12 weeks after treatment completion)
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therapies. Other available drugs (simeprevir+SOF,
PrOD) were not recommended for this patient group [8,
9]. However, daily clinical practice and local conditions
do not always enable rigorous compliance with these
guidelines. Combinations of SOF with NS5A inhibitor
was not available in Poland until November 2015. The
first interferon-free drug which could be used was
PrODR, initially available under the early-access pro-
gram and, beginning from July 2015, under the program
of the National Health Fund.
Due to the urgent need to apply the therapy to numer-
ous queuing patients with advanced fibrosis and cirrho-
sis, they were given an accessible drug, which was
considered a rescue therapy. The first group of patients
(AMBER cohort) also included 16 patients who had
failed triple treatment with boceprevir or telaprevir [14].
SVR was achieved in all these patients. Taking into ac-
count these encouraging results and local realities, the
Polish Group of HCV Experts included this therapeutic
regimen in its recommendations as acceptable for use in
the patients previously treated by PIs. This drug was ap-
proved by the national health insurance institution and
started to be widely used within the framework of the
drug program, first as the only drug and then along with
LSR.
Therefore, the Epi-Ter2 program enabled to gather a
vast group of patients treated with the PrODR regimen
seldom used in other countries.
Description of small patient groups can be mostly
found in the literature, e.g. only 7 patients after PI treat-
ment, who received PrODR therapy, were included in
the Italian VIRONET-C cohort [26].
A large German cohort involving a total of 1017 pa-
tients treated by PrODR [27], included 72 patients
treated previously with TVR or BOC. A Spanish cohort
consisting of 1567 patients included only 49 patients
treated by PrODR [28]. In the aforementioned cohorts,
most of the patients with the history of PI therapy, re-
ceived LSR. Therefore, our patient group is one of the
largest, in which efficacy of PrODR in patients after first
generation PI treatment was evaluated.
In our study, we demonstrated that PrODR regimens
are as effective in this patient group as LSR, including
patients with advanced liver disease irrespective of prior
treatment failure.
Initial concerns were not substantiated that first-
generation PI treatment would be associated with selec-
tion of RASs significantly reducing efficacy of subse-
quent therapies. Any probable RAS faded, and wild virus
type begins dominating within the period of a year after
the end of the PI therapy. Whereas, RASs in NS5A re-
gion characterized by higher durability had a demon-
strable influence on subsequent treatment efficacy,
which proved to be a significant problem [29–31].
The baseline presence of RAS in our patients was not
tested because it is not a routine examination in real-life
setting. For the majority of patients, the period between
the end of the triple drug treatment and the start of the
interferon-free treatment was longer than 12 months.
Both therapy types were characterized by a favourable
safety profile, including cirrhosis patients.
The strength of our study is a large group of patients
treated with the therapeutic regimen, which is relatively
infrequently used in the patients after PI in Western
Europe and USA. Results of our study confirm that
PrODR can be used successfully and equivalently with
other accessible drugs in patients with compensated liver
disease. This can be particularly relevant for countries
where the full scope of the interferon-free therapies is
unavailable, or administrative restrictions in the choice
of drugs exist.
The limitation may be the use of different therapeutic
regimens in individual subgroups of patients (duration
of treatment, addition of RBV) which results from the
fact that the study was conducted in real-life conditions,
without a predetermined protocol. However, all the
therapeutic regimens, used according to the current
label, were characterized by very high efficacy.
Conclusion
In the future, as availability increases, novel, pangenoty-
pic DAAs will surely start dominating. However, as long
as an access to these newest drugs is limited, the drugs
of the previous generation will remain in widespread
use.
The results of our study may be useful in the daily
clinical practice, proving that the patients after failed
IFN-based triple therapies containing PI, can be cured
using both PrODR and LSR regimens with comparable
efficacy and safety.
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